里昂发布研报称，将药明康德（02359）目标价从92.40港元上调至113.70港元；药明康德（603259.SH） 目标价从92.40元人民币上调至103.40元人民币，维持"跑赢大市"投资评级。 药明康德2025年第二季收入及经调整非国际财务报告准则净利润分别同比增长20%及48%，符合2025年 7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引，从10%至15%上调至13%至17%， 自由现金流指引从40亿元至50亿元人民币，上调到50亿元至60亿元人民币。考虑到上半年强劲表现，上 调后的收入指引并不显激进，并重申2025年经调整非国际财务报告准则净利润率将较2024年有所改善。 里昂相应上调药明康德2025至2027年全年收入及净利润预测，幅度分别为3%至4%及13%至17%，以反 映最新指引。 来源：新浪港股 ...

药明康德(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通过了《关于 调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股份的回购股 份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其他内容不 变。 ...

Market Overview - A-shares experienced a significant afternoon rally, with the Shanghai Composite Index regaining above 3600 points, closing up 0.33% at 3609.71 points, while the ChiNext Index rose nearly 2% to 2406.59 points, marking a new high for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan compared to the previous day [1] Sector Performance - The insurance and banking sectors saw declines, while the semiconductor sector surged, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector also showed strong performance, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept experienced a resurgence, with Sanmiao Gene rising over 20% and several other pharmaceutical stocks hitting their daily limit up [1][3] Notable Stocks - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the first half of the year, with a backlog of orders amounting to 56.69 billion yuan, a 37.2% increase year-on-year [4][5] - The stock of Weiwai New Materials surged over 10 times since July, reaching a new high of 90 yuan per share, although the company cautioned that its stock price has significantly deviated from its fundamental situation [10] Future Outlook - WuXi AppTec expects its revenue from ongoing operations to return to double-digit growth, with an upward adjustment of its overall revenue forecast to between 42.5 billion and 43.5 billion yuan [5] - The innovative drug industry is anticipated to enter a new phase, with significant opportunities expected in 2025, driven by upcoming international conferences and ongoing licensing transactions [6] Semiconductor Sector Insights - The semiconductor sector saw strong gains, with Dongxin Co. and Fudan Microelectronics leading the charge [7] - The U.S. government's recent AI Action Plan aims to bolster domestic semiconductor manufacturing while imposing restrictions on exports, which may accelerate the domestic industry's self-sufficiency [9]

今日（7月29日），A股午后拉升走高，沪指重返3600点上方，创业板指涨近2%站上2400点续创年内新 高；港股走势疲弱，但尾盘跌幅有所收窄。 具体来看，沪指早盘窄幅震荡，午后拉升收复3600点，深证成指、创业板指均大幅走高。截至收盘，沪 指涨0.33%报3609.71点，深证成指涨0.64%报11289.41点，创业板指涨1.86%报2406.59点，科创50指数涨 1.45%，沪深北三市合计成交18296亿元，较此前一日增加约630亿元。 市场走势现明显分化，保险、银行板块下挫；半导体板块拉升，东芯股份20%涨停，复旦微电涨近 10%；钢铁板块再度活跃，西宁特钢（600117）、八一钢铁（600581）涨停；创新药概念再度爆发，三 元基因涨超20%，睿智医药（300149）、辰欣药业（603367）等涨停，药明康德（603259）涨近8%； PCB概念延续强势，方邦股份连续两日涨停；CPO概念崛起，天孚通信（300394）涨近14%，中际旭创 （300308）股价突破200元续创历史新高。值得注意的是，10倍大牛股上纬新材盘中突破90元大关，再 创新高。此外，受传闻提振恒生电子（600570）强势涨停，但 ...

Market Overview - A-shares experienced a significant afternoon rally, with the Shanghai Composite Index surpassing 3600 points and the ChiNext Index rising nearly 2% to over 2400 points, marking a new high for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan compared to the previous day [1] Sector Performance - The insurance and banking sectors saw declines, while the semiconductor sector surged, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector also showed strong performance, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept experienced a resurgence, with Sanmiao Gene rising over 20% and several other pharmaceutical stocks hitting their daily limit up [1][4] Notable Stocks - Wu Wei New Materials saw its stock price exceed 90 yuan, marking a new high and a cumulative increase of over 10 times since July [13] - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the reporting period [5] - WuXi AppTec's revenue from ongoing business reached 20.41 billion yuan, with significant contributions from U.S. and European clients [5] Future Outlook - WuXi AppTec expects its ongoing business revenue growth to return to double digits, with an upward adjustment of its overall revenue forecast for the year [6] - The innovative drug industry in China is transitioning to a leading position, with significant opportunities anticipated in 2025, including major international conferences that may showcase promising domestic drug data [7] - The semiconductor sector is expected to benefit from U.S. government measures aimed at strengthening domestic companies and limiting competition from China [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-052 无锡药明康德新药开发股份有限公司 关于调整回购股份价格上限的公告 董事長 李革博士 香港，2025年7月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 本公司董事会及全体董事保证本公告内容 ...

截至2025年7月28日，公司已根据2025年首次股份回购方案透过集中竞价交易方式回购合共6,514,425股 A股，占公司已发行股本总额的0.23%。2025年首次股份回购的最高价为每股A股人民币90.70元。2025 年首次股份回购的最低价为每股A股人民币65.53元。2025年首次股份回购的平均价为每股A股人民币 76.34元。所动用资金总额为人民币497,297,934.64元(不含交易费)。 格隆汇7月29日丨药明康德(02359.HK)公布，鉴于近期公司A股价格持续上涨，基于对公司未来发展的 信心和对公司价值的认可，为保障2025年首次股份回购方案的顺利实施，公司于2025年7月29日举行的 第三届董事会第二十三次会议上审议通过了《关于调整回购股份价格上限的议案》，据此，根据2025年 首次股份回购方案进行股份回购的价格上限调整为人民币114.15元╱股(含)，即不高于董事会批准《关 于调整回购股份价格上限的议案》前30个交易日公司股份交易均价的150%。除上述该调整外，有关 2025年首次股份回购方案的其他事宜维持不变。具体的A股回购数量及占公司已发行股本总额的比例以 2025年首次股份回购完成 ...

Core Viewpoint - The report from Cinda Securities highlights that WuXi AppTec's TEDIS business is driving significant growth, leading the company to raise its full-year performance guidance [1] Financial Performance - In H1 2025, the company is expected to achieve a net profit attributable to shareholders of approximately 8.56 billion yuan, representing a year-on-year increase of 101.9% [1] - In Q2 2025, the adjusted net profit attributable to shareholders is projected to be 3.64 billion yuan, reflecting a year-on-year growth of 47.9% [1] Business Growth Drivers - The strong growth in the company's chemical business is primarily driven by the high demand in the TEDIS segment [1] - The demand for peptides and oligonucleotides remains robust, with a rich order backlog [1] - The company plans to increase its peptide solid-phase synthesis capacity to over 100,000 liters by the end of 2025, indicating a positive outlook for the TEDIS business in the next 1-2 years [1] Global Market Position - Approximately 85% of the company's revenue comes from overseas clients, establishing it as a fully globalized and competitive leader in the CRDMO sector [1] - Despite geopolitical concerns, the business growth from U.S. clients remains strong in H1 2025, alleviating market worries and reinforcing the company's stable position in the global supply chain [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月17日及 2025年5月14日刊發的公告（「該等公告」）；(ii)本公司於2025年3月26日刊發的通 函（「通函」）；(iii)於2025年3月26日刊發的2024年股東週年大會（「2024年股東週 年大會」）通告；及(iv)於2025年4月29日刊發的2024年股東週年大會投票結果公 告，內容有關（其中包括）2025年以集中競價交易方式回購本公司A股股份方案 （「2025年首次股份回購方案」）以及實施2024年度利潤分配及2025年特別股息分 派後調整A股回購價格上限。除非文義另有所指，否則本公告已界定的詞語在 通函及該等公告中具有相同涵義。 I. 有關2025年首次股份回購方案的資料 於2025年4月29日 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [2][10]. Core Views - The TIDES business segment has shown remarkable performance, leading to an upward revision of the full-year revenue guidance [10]. - For the first half of 2025, the company reported a revenue of 20.799 billion RMB, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion RMB, a year-on-year increase of 101.92% [4]. - The company expects revenue growth for its continuing operations to return to double digits, with the growth rate revised from 10-15% to 13-17% [8]. Financial Performance - In H1 2025, the gross margin improved significantly to 44.45%, an increase of 5.08 percentage points year-on-year, while the net profit margin rose to 41.64%, up 16.81 percentage points year-on-year [5]. - The revenue from the chemical business reached 16.3 billion RMB, a growth of 33.5%, while the TIDES business revenue surged to 5.03 billion RMB, a staggering increase of 141.6% [6]. - The company’s total orders on hand reached 56.69 billion RMB, reflecting a year-on-year growth of 37.2% [8]. Revenue and Profit Forecast - The revenue forecast for 2025-2027 has been adjusted to 43.299 billion RMB, 49.656 billion RMB, and 56.472 billion RMB respectively, with net profit forecasts revised to 14.406 billion RMB, 13.249 billion RMB, and 15.249 billion RMB [10][12]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 5.02 RMB, 4.61 RMB, and 5.31 RMB respectively [10].